Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [5] - The company's lead drug candidate, ADX71149, has completed several Phase 2 clinical studies in various conditions including schizophrenia and epilepsy [5] - Addex is also advancing a GABAB PAM program for chronic cough independently, alongside a partnership with Indivior for substance use disorder treatments [5] Product Development - The company announced positive results from its GABAB positive allosteric modulator (PAM) chronic cough program, which will be presented at the Thirteenth London International Cough Symposium [1] - In guinea pig models, the GABAB PAM significantly reduced cough frequency and increased cough latency without showing signs of tolerance after sub-chronic treatment [2] - The GABAB PAM demonstrated a wider safety margin compared to baclofen, a GABAB agonist, which is limited in clinical use due to side effects and short half-life [2][4] Scientific Insights - This is the first time a highly selective GABAB PAM has shown antitussive activity in animal models of cough, indicating its potential as a best-in-class treatment [3] - GABAB receptors are widely expressed in the cough neural circuit, and targeting these receptors with an allosteric modulator is expected to provide advantages such as higher selectivity and better tolerability compared to traditional agonists [4]